If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,248.00    -42.00 (-1.83%)
Bid:
2,240.00
Ask:
2,256.00
Spread: 16.00 (0.714%)
Market Cap: £1.49b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
 

20 September 2011

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price of 1,000 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 45,856 Ordinary Shares which represents 0.08% of the issued share capital of the Company which is currently 60,239,150 Ordinary Shares.

 

Genus also announces that of 46,927 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 46,927 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 1,000 pence per Ordinary Share.

 

Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 41,061 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 1,000 pence per Ordinary Share.

 

Thomas Philip Acton's direct shareholding in the Company now stands at 31,104 Ordinary Shares which represents 0.06% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 1,000 pence per Ordinary Share.

 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost options under the Plan.

 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSURRSRANAKUAR
Date   Source Headline
26th Nov 20104:27 pmRNSHolding(s) in Company
11th Nov 20103:33 pmRNSResult of AGM
11th Nov 20107:00 amRNSAGM and IMS
29th Oct 20102:30 pmRNSTotal Voting Rights
28th Oct 20107:00 amRNSStrategic Progress in India
27th Oct 20102:30 pmRNSAnnual Information Update
14th Oct 201010:00 amRNSAnnual Financial Report and AGM Meeting
30th Sep 20103:30 pmRNSTotal Voting Rights
27th Sep 20102:30 pmRNSDirector/PDMR Shareholding
22nd Sep 20103:16 pmRNSAdditional Listing
22nd Sep 20102:49 pmRNSDirector/PDMR Shareholding
15th Sep 20102:50 pmRNSDirector/PDMR Shareholding
13th Sep 201011:00 amRNSDirector/PDMR Shareholding
10th Sep 20102:00 pmRNSDirector/PDMR Shareholding
7th Sep 20107:01 amRNSBoard Change
7th Sep 20107:00 amRNSPreliminary Results
30th Jul 20102:00 pmRNSBlocklisting Interim Review
5th Jul 20107:00 amRNSPre-Close Trading Statement
17th Jun 20102:30 pmRNSHolding(s) in Company
3rd Jun 20103:30 pmRNSDirector's Shareholding
12th May 20107:00 amRNSInterim Management Statement
30th Apr 20102:00 pmRNSTotal Voting Rights
19th Apr 20102:58 pmRNSHolding(s) in Company
7th Apr 20102:00 pmRNSHolding(s) in Company
1st Apr 20102:30 pmRNSDirector/PDMR Shareholding
2nd Mar 20103:00 pmRNSDirector/PDMR Shareholding
26th Feb 20109:17 amRNSHolding(s) in Company
25th Feb 20107:00 amRNSSenior Management Appointments
25th Feb 20107:00 amRNSInterim Results
22nd Feb 20103:33 pmRNSHolding(s) in Company
29th Jan 201010:00 amRNSBlocklisting 6 Monthly Return
26th Jan 20107:00 amRNSNotice of Results
14th Jan 20105:27 pmRNSHolding(s) in Company
4th Jan 20107:00 amRNSTotal Voting Rights
30th Nov 20094:00 pmRNSTotal Voting Rights
30th Nov 20092:00 pmRNSDirector/PDMR Shareholding
17th Nov 20094:20 pmRNSHolding(s) in Company
13th Nov 20092:00 pmRNSDirector/PDMR Shareholding
12th Nov 20093:25 pmRNSResult of AGM
12th Nov 20092:15 pmRNSAGM and Interim Management Statement
30th Oct 20092:00 pmRNSTotal Voting Rights
27th Oct 20092:00 pmRNSAnnual Information Update
9th Oct 20093:58 pmRNSAnnual Financial Report and AGM
30th Sep 20092:00 pmRNSTotal Voting Rights
28th Sep 20094:10 pmRNSDirector/PDMR Shareholding
16th Sep 20092:30 pmRNSDirector/PDMR Shareholding
15th Sep 20092:32 pmRNSDirector/PDMR Shareholding
10th Sep 20094:37 pmRNSDirector/PDMR Shareholding
10th Sep 20097:00 amRNSBovine Research And Development Success
10th Sep 20097:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.